Selected novel anticancer treatments targeting cell signaling proteins

被引:55
作者
Elsayed, YA [1 ]
Sausville, EA [1 ]
机构
[1] NCI, Dev Therapeut Program, Div Canc Treatment & Diagnosis, NIH,Clin Trials Unit, Rockville, MD 20852 USA
关键词
cell cycle; cyclin-dependent kinase; tyrosine kinase inhibitor; chemotherapy; histone deacetylase inhibitor; proteasome inhibitor;
D O I
10.1634/theoncologist.6-6-517
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Empirical approaches to discovery of anticancer drugs and cancer treatment have made limited progress in the cure of cancer in the last several decades. Recent advances in technology and expanded knowledge of the molecular basis of tumorigenesis and metastasis have provided unique opportunities to design novel compounds that rationally target the abnormal molecular and biochemical signals leading to cancer. Several such novel agents have completed advanced stages in clinical development. The excellent clinical results achieved by some of these compounds are creating new paradigms in management of patients with neoplastic diseases. Clinical development of these agents also raises challenges to the traditional methods of drug evaluation and measurement of efficacy.
引用
收藏
页码:517 / 537
页数:21
相关论文
共 191 条
[1]  
Adams J, 1999, CANCER RES, V59, P2615
[2]  
AGAHJANIAN C, 2001, P AN M AM SOC CLIN, V20, pA338
[3]  
AKINAGA S, 1991, CANCER RES, V51, P4888
[4]   Differential effects of UCN-01, staurosporine and CGP 41 251 on cell cycle progression and CDC2 cyclin B1 regulation in A431 cells synchronized at M phase by nocodazole [J].
Akiyama, T ;
Shimizu, M ;
Okabe, W ;
Tamaoki, T ;
Akinaga, S .
ANTI-CANCER DRUGS, 1999, 10 (01) :67-78
[5]  
Akiyama T, 1997, CANCER RES, V57, P1495
[6]  
Al Hazaa A, 2000, CLIN CANCER RES, V6, p4542S
[7]   TRANSFORMING P21(RAS) MUTANTS AND C-ETS-2 ACTIVATE THE CYCLIN D1 PROMOTER THROUGH DISTINGUISHABLE REGIONS [J].
ALBANESE, C ;
JOHNSON, J ;
WATANABE, G ;
EKLUND, N ;
VU, D ;
ARNOLD, A ;
PESTELL, RG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (40) :23589-23597
[8]   Protease inhibitor-induced apoptosis:: accumulation of wt p53, p21WAF1/CIP1 and induction of apoptosis are independent markers of proteasome inhibition [J].
An, WG ;
Hwang, SG ;
Trepel, JB ;
Blagosklonny, MV .
LEUKEMIA, 2000, 14 (07) :1276-1283
[9]  
Arguello F, 1998, BLOOD, V91, P2482
[10]   Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin [J].
Baselga, J ;
Pfister, D ;
Cooper, MR ;
Cohen, R ;
Burtness, B ;
Bos, M ;
D'Andrea, G ;
Seidman, A ;
Norton, L ;
Gunnett, K ;
Falcey, J ;
Anderson, V ;
Waksal, H ;
Mendelsohn, J .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (04) :904-914